CancerDrs Find care

Testicular Cancer clinical trials in Tennessee

8 actively recruiting testicular cancer trials at 10 sites across Tennessee.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Tennessee:
  • T C Thompson Children's Hospital — Chattanooga, Tennessee
  • Memorial Hospital — Chattanooga, Tennessee
  • Pulmonary Medicine Center of Chattanooga-Hixson — Hixson, Tennessee
  • East Tennessee Childrens Hospital — Knoxville, Tennessee
  • Saint Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Tennessee:
  • T C Thompson Children's Hospital — Chattanooga, Tennessee
  • East Tennessee Childrens Hospital — Knoxville, Tennessee
  • The Children's Hospital at TriStar Centennial — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Tennessee:
  • University Cancer Specialists - Alcoa — Alcoa, Tennessee
  • Vanderbilt-Ingram Cancer Center Cool Springs — Franklin, Tennessee
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ov…

Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Sites in Tennessee:
  • Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Tennessee:
  • Bristol Regional Medical Center — Bristol, Tennessee
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Wellmont Holston Valley Hospital and Medical Center — Kingsport, Tennessee
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Tennessee:
  • Massive Bio SYNERGY-AI site — Memphis, Tennessee
  • Massive Bio SYNERGY-AI site — Nashville, Tennessee
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Tennessee:
  • Research Site — Chattanooga, Tennessee
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20